Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non–small cell lung carcinoma based on Chinese population

Translational Oncology

Volumn 7, Issue 6, 2014, Pages 795-799

  Han, Xiaohong ^a   Zhang, Zhishang ^a   Wu, Di ^a   Shen, Yinchen ^a   Wang, Shuai ^a   Wang, Lin ^a   Liu, Yutao ^a   Yang, Sheng ^a   Hu, Xingsheng ^a   Feng, Yun ^a   Sun, Yan ^a   Shi, Yuankai ^a  

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; CANCER SURGERY; CANCER TISSUE; CHINESE; CYTOLOGY; DNA EXTRACTION; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NON SMALL CELL LUNG CANCER; ONCOLOGICAL PARAMETERS; PATHOLOGY; SEX; SMOKING HABIT; TUMOR BIOPSY; TUMOR VOLUME;

EID: 84915797007     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.10.008     Document Type: Article

References (36)

1. D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, and Felip E (2010). ESMO Guidelines Working Group. Metastatic non–small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl. 5), v116–v119.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, Olak J, Stover D, Strawn JR, Turrisi AT, and Somerfield MR, American Society of Clinical Oncology (2004). American Society of Clinical Oncology treatment of unresectable non–small cell lung cancer guideline: update 2003. J Clin Oncol 22, 330–353.
3. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, and Suh C, et al (2012). First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30, 1122–1128.
4. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, and Hu C, et al (2013). Icotinib versus gefitinib in previously treated advanced non– small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 noninferiority trial. Lancet Oncol 14, 953–961.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, and Sanchez JM, et al (2012). Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non–small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239–246.
6. Azzoli CG, Baker Jr S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, and Milton D, et al, American Society of Clinical Oncology (2009). American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non–small-cell lung cancer. J Clin Oncol 27, 6251–6266.
7. D’Addario G and Felip E, ESMO Guidelines Working Group (2008). Non– small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl. 2), ii39–ii40.
8. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, and Van Schil PE, et al (2011). International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6, 244–285.
9. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, and Franklin W, et al (2013). Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 137, 668–684.
10. Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T, Whiteley J, Donald E, McCormack R, and Todo T (2012). An evaluation study of EGFR mutation tests utilized for non–small-cell lung cancer in the diagnostic setting. Ann Oncol 23, 2914–2919.
11. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, and Squire J, et al (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8, 823–859.
12. Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, Munavvar M, Ng BJ, Rassl DM, and Falzon M, et al (2012). Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non–small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 185, 1316–1322.
13. Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, and Yoshino I, et al (2010). EML4-ALK fusion gene assessment usingmetastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 16, 4938–4945.
14. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino- Kenudson M, Lauwers GY, Loda M, and Fuchs CS (2005). Sensitive sequencing method for KRASmutation detection by pyrosequencing. JMol Diagn 7, 413–421.
15. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, and Makrigiorgos GM (2008). Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14, 579–584.
16. Eberhard DA, Giaccone G, and Johnson BE, Non–Small-Cell Lung Cancer Working Group (2008). Biomarkers of response to epidermal growth factor receptor inhibitors in non–small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 26, 983–994.
17. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, and Smit E, et al (2010). Consensus for EGFR mutation testing in non–small cell lung cancer: results from a European workshop. J Thorac Oncol 5, 1706–1713.
18. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, Tang C, Ellison G, McCormack R, and Ji Q (2013). The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non–small cell lung cancer: comparison of methodologies. J Clin Pathol 66, 1065–1069.
19. Wang S, Yu B, Ng CC, Mercorella B, O'Toole S, and Cooper WA (2014). Mutation testing in non–small cell lung cancer - suitability of small biopsyand cytology specimens. Pathology 46(Suppl. 1), S118.
20. Vallee A, Sagan C, Le Loupp AG, Bach K, Dejoie T, and Denis MG (2013). Detection of EGFR gene mutations in non–small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol 43, 1045–1051.
21. Xu S, Jiang J, Yu X, Sheng D, Zhu T, and Jin M (2014). Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non–small cell lung cancer patients. Lung Cancer 83, 341–346.
22. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, and Yang PC (2014). A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9, 154–162.
23. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, and Kris MG (2011). Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29, 2066–2070.
24. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, and Provencio M, et al (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958–967.
25. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, and Ichinose Y, et al (2009). Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947–957.
26. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, and Squire J, et al (2013). College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15, 415–453.
27. Chinese Association of Oncologists Chinese Society for Clinical Cancer Chemotherapy (2013). The diagnosis and treatment guideline of Chinese patients with EGFR mutation and ALK fusion gene-positive non–small cell lung cancer (2013 version). Zhonghua Zhong Liu Za Zhi 35, 478–480.
28. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, and Nishio M (2007). Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non–small cell lung cancer. Chest 131, 1628–1634.
29. Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, and Mok TS (2014). Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samplesand cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer 83, 174–181.
30. Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, Rossi G, Skov BG, Weynand B, and Bubendorf L, et al (2012). The challenge of NSCLC diagnosis and predictive analysis on small samples: practical approach of a working group. Lung Cancer 76, 1–18.
31. Kulesza P, Ramchandran K, and Patel JD (2011). Emerging concepts in the pathology and molecular biology of advanced non–small cell lung cancer. Am J Clin Pathol 136, 228–238.
32. Moreira AL and Thornton RH (2012). Personalized medicine for non–small cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer 13, 334–339.
33. Aisner DL and Marshall CB (2012). Molecular pathology of non–small cell lung cancer: a practical guide. Am J Clin Pathol 138, 332–346.
34. Varella-Garcia M (2006). Stratification of non–small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1, 19–28.
35. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, and Guo M (2011). EGFR and KRAS mutations in lung carcinoma. Cancer Cytopathol 119, 111–117.
36. Albanna AS, Kasymjanova G, Robitaille C, Cohen V, Brandao G, Pepe C, Small D, and Agulnik J (2014). Comparison of the yield of different diagnostic procedures for cellular differentiation and genetic profiling of non–small-cell lung cancer. J Thorac Oncol 9, 1120–1125.